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ABSTRACT
Objectives Juvenile idiopathic arthritis ( JIA) is a
heterogeneous group of conditions uniﬁed by the
presence of chronic childhood arthritis without an
identiﬁable cause. Systemic JIA (sJIA) is a rare form of
JIA characterised by systemic inﬂammation. sJIA is
distinguished from other forms of JIA by unique clinical
features and treatment responses that are similar to
autoinﬂammatory diseases. However, approximately half
of children with sJIA develop destructive, long-standing
arthritis that appears similar to other forms of JIA. Using
genomic approaches, we sought to gain novel insights
into the pathophysiology of sJIA and its relationship with
other forms of JIA.
Methods We performed a genome-wide association
study of 770 children with sJIA collected in nine
countries by the International Childhood Arthritis
Genetics Consortium. Single nucleotide polymorphisms
were tested for association with sJIA. Weighted genetic
risk scores were used to compare the genetic
architecture of sJIA with other JIA subtypes.
Results The major histocompatibility complex locus and
a locus on chromosome 1 each showed association with
sJIA exceeding the threshold for genome-wide
signiﬁcance, while 23 other novel loci were suggestive of
association with sJIA. Using a combination of genetic
and statistical approaches, we found no evidence of
shared genetic architecture between sJIA and other
common JIA subtypes.
Conclusions The lack of shared genetic risk factors
between sJIA and other JIA subtypes supports the
hypothesis that sJIA is a unique disease process and
argues for a different classiﬁcation framework. Research
to improve sJIA therapy should target its unique genetics
and speciﬁc pathophysiological pathways.
INTRODUCTION
Juvenile idiopathic arthritis ( JIA) encompasses a
heterogeneous group of chronic childhood arthri-
tides that develop without identiﬁable cause and
last more than 6 weeks.1 2 Children with JIA are
placed into seven mutually exclusive categories
based on clinical presentation: oligoarticular arth-
ritis (oligoJIA) affects four or fewer joints; rheuma-
toid factor (RF)-negative polyarthritis (RF–polyJIA)
involves ﬁve or more joints; RF-positive polyarthri-
tis (RF+polyJIA) is analogous to adult rheumatoid
arthritis; psoriatic arthritis (PsA) is an arthritis that
accompanies psoriasis; enthesitis-related arthritis
encompasses non-PsA childhood spondyloarthropa-
thy; systemic arthritis (sJIA, previously known as
Still’s disease) is characterised by prominent sys-
temic inﬂammation and has a rare adult-onset
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counterpart;3 and undifferentiated arthritis includes arthritis
that does not ﬁt into any single category.1 2
sJIA is among the most severe childhood inﬂammatory dis-
eases. First described by Sir George Frederic Still over a century
ago, sJIA is marked by arthritis and systemic inﬂammation with
quotidian fever, evanescent salmon pink skin rash, lymphaden-
opathy, hepatosplenomegaly and serositis.2 4 It is frequently
complicated by macrophage activation syndrome, a potentially
lethal form of hemophagocytic lymphohistiocytosis.5 Although
sJIA only constitutes approximately 10% of JIA in populations
of European descent,1 5 its disproportionately large share of the
morbidity and mortality observed in JIA6 underscores the
importance of understanding and targeting its root causes.
The unique clinical characteristics of sJIA suggest that it is dis-
tinct from other forms of JIA, leading to the contention by
some that sJIA should be separated from other forms of JIA and
labelled as an autoinﬂammatory disease.7 This has been chal-
lenged by identiﬁcation of autoantibodies in some patients with
sJIA.8 Furthermore, while the systemic inﬂammatory features of
sJIA seem to distinguish it from other forms of JIA, most chil-
dren with sJIA eventually shed these features, leaving up to half
of children with a persistent form of arthritis that is similar to
the oligoarticular and polyarticular forms of JIA.5 9 Finally, sig-
niﬁcant differential effects of anticytokine agents have been
observed between sJIA and other forms of JIA.10 However, due
to the highly variable therapeutic responses to each agent in
sJIA, this has not concretely advanced our understanding of
how sJIA mechanistically relates to other forms of JIA.
One approach to evaluate the similarity of diseases is to
examine shared pathophysiology through statistical comparisons
of disease-speciﬁc genetic association data.11 For example,
studies of inﬂammatory bowel disease and spondyloarthritis
have identiﬁed shared genetic risk factors, providing rationale
for similar treatment choices.11 In JIA, the majority of genetic
and genomic investigations have focused on the combination of
the most common subtypes, oligoJIA and RF–polyJIA (hence-
forth referred to in this manuscript as polygoJIA),12 13 but until
recently,14 because of insufﬁcient numbers of patients with sJIA,
there have been only underpowered genetic studies and no
genome-wide studies of sJIA. Comparisons of the genomic
underpinnings of sJIA relative to other forms of JIA have there-
fore also been lacking.
To gain insight into the pathogenesis of sJIA, we established
the International Childhood Arthritis Genetics (INCHARGE)
consortium. Together, we gathered the largest sJIA study popu-
lation ever assembled, which included 982 children from nine
countries on three continents. Using this collection, we per-
formed the ﬁrst genome-wide association study (GWAS) of sJIA.
We recently reported the results of our intensive examination of
the major histocompatibility complex (MHC) locus in this study
population, which identiﬁed the class II human leucocyte
antigen (HLA) region as a strong sJIA susceptibility locus.14
Here, we report the ﬁndings of the GWAS, beyond the MHC
locus. Using the GWAS results, we have performed the ﬁrst
direct comparison of the genetic architecture of sJIA with those
of the most common forms of JIA.
METHODS
Study design and participants
Peripheral blood specimens were collected from children diag-
nosed with sJIA according to the International League of
Associations for Rheumatology (ILAR) criteria2 by paediatric
rheumatologists at participating medical centres in nine coun-
tries (see online supplementary text and ﬁgure S1). Blood
samples were also obtained from geographically matched control
subjects. In addition, single nucleotide polymorphism (SNP)
genotype data from geographically matched control populations
were used, when available. The INCHARGE project was granted
institutional review board (IRB) approval by the University of
Manchester. Subjects were enrolled in accordance with all local
ethics regulations, with the approval of local IRBs at each contrib-
uting medical centre, and with informed parental consent.
Genotyping, quality control and imputation
Genomic DNA was extracted from peripheral blood samples.
Samples were genotyped at the National Human Genome
Research Institute (Bethesda, Maryland, USA) using Human
Omni1M arrays (Illumina) in accordance with the manufac-
turer’s protocols. SNP genotype data were stratiﬁed by country
of origin and rigorous quality control (QC) operations were
undertaken separately in each case and control population, as
previously reported.14 Principal components analysis and multi-
dimensional scaling were used in each geographically deﬁned
case–control collection to generate nine ancestrally matched
case–control strata, as previously described.14 Genomic control
inﬂation factors were calculated, per stratum, as an objective
metric of ancestral matching.14 An overview of the QC para-
meters is shown in online supplementary ﬁgure S2, and com-
plete details are provided in the online supplementary text and
our previous publication.14
SNP genotypes were phased using IMPUTE2,15 and SNP
imputation was performed separately for each geographically
deﬁned stratum using IMPUTE2 software and the multiancestral
1000 Genomes Project dataset (phase III) as the reference popu-
lation.16 Genotype probabilities for common markers (case
minor allele frequency ≥0.04) that were imputed with high
quality (info scores ≥0.8) were included in subsequent analyses.
Statistical analysis
Association testing of genotype probabilities was performed
using logistic regression in each geographically deﬁned stratum
with SNPTESTv2,15 adjusting for gender and ancestry inform-
ative principal components. Association results were
meta-analysed using GWAMA.17 Heterogeneity was evaluated in
the meta-analyses using the I2 statistic. Weighted genetic risk
scores (wGRSs) were calculated and receiver operator character-
istic (ROC) curve analyses were performed according to the
method of Karlson et al.18 wGRSs were calculated as the sum of
the risk allele counts, weighted by the natural logarithm of the
OR. The wGRS for polygoJIA (polygo-wGRS) incorporated 23
independent risk alleles reported by Hinks et al12 (see online
supplementary table S1). The wGRS for RF+polyJIA (RF
+poly-wGRS) was based on the RF+polyJIA-associated
wGRS-1119 (see online supplementary table S2). The case and
control distributions of risk alleles and wGRSs were evaluated
with the Wilcoxon rank-sum test. Association of wGRSs with
sJIA was tested by logistic regression, adjusted for ancestry and
gender. The ability of wGRSs to discriminate between sJIA and
other JIA subtypes was evaluated with ROC curve analysis and
calculation of the area under the curve (AUC) using
R. Quantile–quantile (Q–Q) plots were generated using the sJIA
association data, conditional on sets of polygoJIA-associated
SNPs,12 as previously described.20
RESULTS
We performed SNP genotyping of 1413 children, including 982
children with sJIA and 431 healthy children. SNP genotype
data, in silico, were incorporated from ﬁve existing control
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populations, including 7579 additional subjects, producing a
total study population of 8992 individuals. After stringent QC,
770 patients with sJIA and 6947 control subjects were stratiﬁed
into nine geographically deﬁned and ancestrally matched case–
control collections (table 1, see online supplementary text and
tables S3 and S4), as previously described.14 Because most in
silico control datasets were generated using SNP genotyping
platforms different from that used in our study, the ﬁnal
number of SNPs evaluated in strata with in silico data was
reduced to the intersection of the different SNP arrays (see
online supplementary text and table S4). Imputation produced
sets of between 4 147 566 and 6 832 892 imputed SNPs that
passed postimputation QC processes (see online supplementary
text). Association results were combined by ﬁxed-effect
meta-analysis, producing meta-analytic association data for
5 600 610 SNPs (ﬁgure 1). This analysis identiﬁed two sJIA sus-
ceptibility loci with associations exceeding the threshold for
genome-wide signiﬁcance, adjusted for the two models tested
(p<2.5×10−8), and 23 loci with highly suggestive evidence of
association (p<5×10−6; table 2). With the exception of the
MHC locus none of these loci have been previously implicated
in sJIA risk or pathophysiology. The strongest sJIA risk locus
identiﬁed by this study was the MHC locus on chromosome 6
(see online supplementary ﬁgure S3). We have recently
described this association in great detail in the context of a
regional association study of the MHC locus in sJIA.14 Beyond
the MHC locus, we identiﬁed a novel sJIA susceptibility locus
on the short arm of chromosome 1 (1p36.32) whose association
also exceeded the threshold for genome-wide signiﬁcance under
the additive model (ﬁgures 1 and 2). This locus includes a
cluster of 14 sJIA-associated SNPs that span 20.6 kb; the peak
SNP is rs72632736 (p=2.9×10−9; OR 2.4 (1.8, 3.3). The asso-
ciation peak is located 20 kb upstream of LOC284661, a long
intergenic non-coding RNA, and 263.5 kb upstream of the
nearest protein coding gene, AJAP1, encoding adherens
junction-associated protein 1. Examination of ENCODE
(Encyclopedia of Noncoding DNA Elements) data revealed that
the sJIA-associated SNPs overlaid a cluster of transcription
factor-binding sites (TFBS) identiﬁed by chromatin immunopre-
cipitation sequencing (ChIP-seq; ﬁgure 2) in a variety of cell
types; however, none of the top sJIA-associated SNPs were
located within the ChIP-seq TFBS.
In addition to the two loci described above, this study identi-
ﬁed 23 novel candidate susceptibility loci (ﬁgure 1, table 2),
Table 1 Summary of SNP datasets from nine sJIA case–control
collections after quality control operations
Stratum Cases Controls
Genotyped
SNPs (filtered) Imputed
Imputed
SNPs
(filtered)
USA 243 1718 476 196 18 263 974 6 189 397
UK 202 4097 440 688 18 263 701 6 255 387
Germany 115 193 682 516 18 266 121 6 391 432
Turkey 49 94 682 598 18 270 612 6 389 103
Italy 49 59 686 397 18 269 173 6 375 260
Brazil 48 62 740 509 18 263 563 6 698 947
Argentina 33 115 659 100 18 263 401 6 129 601
Canada 17 427 396 935 18 263 146 5 812 530
Spain 14 182 156 136 18 261 199 4 147 550
Total 770 6947
sJIA, systemic juvenile idiopathic arthritis; SNP, single nucleotide polymorphism.
Figure 1 Genome-wide association results from meta-analysis of nine INCHARGE sJIA collections. The threshold of genome-wide signiﬁcance
(p<2.5×10−8) is shown by the blue line, while the orange line marks the level of signiﬁcance suggestive of association (p<5×10−6). The top 10
sJIA-associated loci are labelled with the name of the nearest gene(s). INCHARGE, International Childhood Arthritis Genetics Consortium; MHC,
major histocompatibility complex; sJIA, systemic juvenile idiopathic arthritis.
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two of which are shown in detail in online supplementary ﬁgure
S4. Importantly, the top 25 sJIA susceptibility loci had scant
intersection with the known susceptibility loci of other JIA sub-
types. Based on this observation, we sought to compare the
genetic architecture of sJIA with those of polygoJIA and RF
+polyJIA.
We ﬁrst examined the 23 polygoJIA-associated loci reported
by Hinks et al12 in the sJIA study population and none showed
even a modest association with sJIA (see online supplementary
tables S5 and S6). To more formally compare sJIA with
polygoJIA, we calculated a polygo-wGRS in the sJIA case–
control collections based on the same 23 SNPs. The non-
parametric Wilcoxon rank-sum test found no difference in the
distribution of polygoJIA risk allele counts or polygo-wGRSs
between sJIA cases and controls (ﬁgure 3, see online
supplementary table S7 and ﬁgures S5 and S6). Consistent with
this, logistic regression analysis found no correlation between
the polygo-wGRS and sJIA in any individual stratum or in the
full study population (see online supplementary table S7).
Analysis of ROC curves in individual strata and the full popula-
tion found that the AUCs for polygo-wGRS were all close to
0.5, indicating that the polygo-wGRS was no better than
random chance at distinguishing sJIA cases from control subjects
(ﬁgure 3, see online supplementary ﬁgure S7). Finally, to
expand the scope of our comparison beyond peak SNPs from
risk loci, we performed a Q–Q plot-based enrichment analysis
to look for shared genetic risk factors between sJIA and
polygoJIA (ﬁgure 3). By comparing Q–Q plots of
polygoJIA-associated SNPs12 at several different signiﬁcance
levels in our sJIA collection, we sought to evaluate pleiotropy in
a more global/genomic manner. In the presence of pleiotropy,
the slopes of the Q–Q plots of disease A associations are
expected to increase as the plotted SNP sets become more
strongly associated with disease B, as previously shown.20 In the
case of polygoJIA-associated SNPs in sJIA, the slope of the Q–Q
plots of sJIA associations did not increase when SNPs of increas-
ingly strong association with polygoJIA were plotted, indicating
that there was no enrichment of sJIA-associated variants among
polygoJIA-associated variants, and therefore that there was no
evidence of pleiotropy (ﬁgure 3).
In addition, we used an RF+poly-wGRS19 to look for shared
genetic architecture between sJIA and RF+polyJIA. As was the
case with polygoJIA, non-parametric testing revealed no signiﬁ-
cant difference in the distribution of RF+polyJIA risk alleles
(see online supplementary ﬁgure S8) or RF+poly-wGRS (see
online supplementary ﬁgure S9) between sJIA cases and controls
in any individual population. Of note, non-parametric testing
and logistic regression analysis identiﬁed a signiﬁcant difference
in RF+poly-wGRS between sJIA and controls in the full collec-
tion (see online supplementary table S8 and ﬁgure S10);
however, the wGRSs were actually lower in the sJIA cases than
in the controls (see online supplementary ﬁgure S11).
Consistent with these observations, ROC analyses found that
the RF+poly-wGRS was not predictive of sJIA (see online
Table 2 Susceptibility loci with at least suggestive evidence of association with sJIA
Top SNP Chr Position Ref/Alt Best p Value Model OR (CI) i2 Strata Samples Closest gene(s)
rs41291794 6 32425762 A/T 3.6×10−15 Additive 2.1 (1.8 to 2.6) 0.64 9 7711 HLA-DRA
rs72632736 1 4449204 A/G 2.9×10−9 Additive 2.4 (1.8 to 3.3) 0 7 7075 LOC284661, AJAP1
rs1823549 1 103147831 T/C 3.2×10−7 Additive 0.4 (0.3 to 0.6) 0 6 6816 COL11A1
rs1178121 7 18762652 C/A 3.4×10−7 Dominant 1.6 (1.3 to 1.9) 0.24 8 7513 HDAC9
rs12517545 5 73680314 G/A 5.2×10−7 Dominant 0.6 (0.5 to 0.8) 0 9 7711 ENC1, LOC101929082
rs79575701 18 45579621 C/A 6.2×10−7 Additive 3.4 (2.1 to 5.5) 0 4 4822 ZBTB7C
rs114940806 1 44558672 A/G 1.2×10−6 Additive 3.0 (1.9 to 4.7) 0.47 5 5137 KLF17
rs1279094 9 11706771 T/C 1.2×10−6 Additive 1.3 (1.2 to 1.5) 0 9 7712 LOC101929446
rs864089 3 64244118 T/C 1.4×10−6 Dominant 0.6 (0.5 to 0.8) 0 8 7516 PRICKLE2
rs481331 10 43003048 A/T 1.4×10−6 Additive 1.5 (1.3 to 1.7) 0 9 7712 ZNF37BP, ZNF33B
rs8097070 18 23086307 A/G 1.6×10−6 Additive 0.3 (0.2 to 0.5) 0 4 4993 ZNF521, SS18
rs1527934 8 117392156 C/T 1.8×10−6 Additive 1.7 (1.4 to 2.1) 0 6 6926 EIF3H, LINC00536
rs78507369 16 78305293 A/G 2.0×10−6 Additive 3.0 (1.9 to 4.6) 0 4 4857 WWOX, LSM3P5
rs12445022 16 87575332 G/A 2.4×10−6 Dominant 1.5 (1.3 to 1.7) 0.36 9 7715 LOC101928737, JPH3
rs112165031 2 112902227 G/A 2.5×10−6 Additive 2.5 (1.7 to 3.7) 0.58 5 6917 FBLN7
rs6853094 4 116576274 C/A 2.6×10−6 Additive 1.6 (1.3 to 1.9) 0.22 8 7564 RPF2P2, PGAM4P2
rs73401585 10 109690236 T/C 2.6×10−6 Additive 3.2 (2.0 to 5.2) 0 4 4824 LOC101927573, SORCS1
rs9595973 13 49286438 G/A 2.8×10−6 Dominant 2.8 (1.8 to 4.3) 0.5 4 6845 CYSLTR2
rs9633402 1 247946160 G/A 3.0×10−6 Dominant 0.4 (0.2 to 0.6) 0 9 7708 TRIM58
rs62438583 6 75326244 T/G 3.4×10−6 Dominant 0.7 (0.6 to 0.8) 0 9 7712 LOC101928516, COL12A1
rs62359376 5 52411328 G/A 3.6×10−6 Dominant 1.7 (1.4 to 2.2) 0.13 8 7516 LOC257396, MOCS2
rs1501138 4 16397067 T/C 4.0×10−6 Dominant 0.3 (0.2 to 0.5) 0.24 8 7517 LDB2, TAPT1, ZEB2P1
rs7712113 5 4985443 G/C 4.5×10−6 Dominant 3.7 (2.1 to 6.5) 0.68 4 4661 LINC01020, LOC101929176
rs1885747 14 93047455 A/G 4.6×10−6 Additive 1.4 (1.2 to 1.7) 0.38 8 7513 RIN3, LGMN
rs111580313 16 86621219 C/T 4.8×10−6 Dominant 1.7 (1.4 to 2.2) 0 7 7368 MTHFSD, FOXL1, FOXC2
Best p value, meta-analytic p value corrected for gender and ancestry under the model specified in the Model column. Model, the genetic model (either additive or dominant) that
showed the strongest association between the SNP and sJIA. I2, I2 test for heterogeneity. Strata, number of strata included in meta-analysis. Samples, number of samples included in
meta-analysis.
Alt, alternate allele; Chr, chromosome; Ref, reference allele; sJIA, systemic juvenile idiopathic arthritis; SNP, single nucleotide polymorphism;
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supplementary ﬁgures S10 and S12). Collectively, these investi-
gations failed to identify any evidence of shared genetic archi-
tecture between sJIA and polygoJIA or RF+polyJIA.
DISCUSSION
In this study, two novel susceptibility loci met genome-wide sig-
niﬁcance criteria for association with sJIA and 23 other loci
demonstrated highly suggestive evidence of association.
Furthermore, formal comparisons of association data from sJIA
with those from polygoJIA and RF+polyJIA have demonstrated
that sJIA bears a unique genetic architecture, indicating that its
underlying pathophysiological mechanisms are signiﬁcantly
divergent from other forms of JIA. This has important implica-
tions and should direct research for future targets of therapeutic
intervention for children affected with sJIA.
This is the ﬁrst large-scale genomic study of sJIA, which
includes case–control collections from nine different countries.
In a sample of 982 affected children, we identiﬁed genome-wide
signiﬁcant evidence of association with SNPs in the class II
MHC locus and SNPs on chromosome 1 nearest to an unchar-
acterised long non-coding RNA gene. This work also identiﬁed
many additional candidate sJIA susceptibility loci, nearly all of
them novel, and aside from the HLA locus, none of these novel
loci are associated with any other rheumatic diseases (see online
supplementary table S9). The identiﬁcation of these loci is an
important step towards the elucidation of the speciﬁc pathways
and pathogenic mechanisms in sJIA, which in turn will allow
the development of therapies to more speciﬁcally target sJIA
pathophysiology in affected children. Several of the susceptibil-
ity loci that warrant further investigation include strong candi-
dates for therapeutic modulation, and many novel loci or genes
that have been poorly studied, to date. Functional investigations
are needed to identify and understand the speciﬁc mechanisms
that underlie the genetic associations.
This study also provided the ﬁrst opportunity to demonstrate
that sJIA did not share heritable risk factors with the more
common oligoarticular and polyarticular forms of JIA. There
was no intersection of the top susceptibility loci of sJIA with
those of polygoJIA or RF+polyJIA. Even within the class II
MHC region, which harbours disease-associated genetic vari-
ation in each of these categories of JIA, the subtype-speciﬁc risk
factors (SNPs, HLA alleles and HLA haplotypes) are not shared
between subtypes. Using a combination of genetic risk scores
and enrichment analysis, this study reveals an absence of shared
genetic architecture between sJIA and either polygoJIA or RF
+polyJIA, despite often sharing a chronic arthritis feature with
polygo or RF+polyJIA. It could be that as a clinical feature,
arthritis is a non-speciﬁc ﬁnding that is present in many differ-
ent conditions, including infections, malignancies, autoimmune
disorders and autoinﬂammatory conditions. These distinct
genetic data provide hard evidence that these conditions differ
in pathophysiology, strongly supporting the clinical distinction
Figure 2 Systemic juvenile idiopathic arthritis (sJIA) susceptibility locus at chr1p36.32. A regional association plot demonstrates the association
between sJIA) and single nucleotide polymorphisms (SNPs) in this region (A). The effect of the peak SNP (rs72632736) in each study population is
demonstrated in the forest plot (B). The threshold of genome-wide signiﬁcance (p<2.5×10−8) is marked by the black horizontal line in (A) and (C).
Panel C shows the superimposition of sJIA-associated SNPs (inset box, A) with transcription factor-binding sites determined by chromatin
immunoprecipitation (ChIP) sequencing from the Encyclopedia of Noncoding DNA Elements (ENCODE) project.
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between sJIA and the other JIA subtypes. Considering the
ongoing discussions about restructuring the JIA nomenclature,
these studies will help inform and guide the debate surrounding
sJIA7 and how it should be classiﬁed.
The genetic dissimilarity of sJIA and other JIA subtypes has
important therapeutic implications for children with sJIA.
Currently, the treatment of sJIA presents physicians with a clin-
ical conundrum, with no single, universally effective therapeutic
approach. Prior to the era of biological response-modifying
agents, sJIA was treated with disease-modifying antirheumatic
drugs, including methotrexate, with a rationale for use extrapo-
lated from other forms of JIA; there were no clinical trials and
only limited outcome studies describing their effectiveness in
sJIA.10 In the absence of clear therapeutic alternatives, and
despite the limited evidence of efﬁcacy, methotrexate remains an
accepted therapeutic option in the consensus treatment proto-
col.21 Similarly, therapies targeting the cytokine tumour necrosis
factor-α are highly effective in the treatment of other forms of
JIA,22 but show only modest effect in children with sJIA.10
Today, even with the most effective treatments for sJIA directed
against the inﬂammatory cytokines interleukin (IL)-1 and
IL-6,10 a sizable proportion of children continue to have active
disease, with chronic arthritis persisting in nearly 40% of chil-
dren in a recent study.9 Currently, the only widely effective
treatment for sJIA remains large doses of glucorticoids.10 There
is clearly an imperative to look for root causes of sJIA to iden-
tify better targets for therapy and prevent the development of
persistent, disabling arthritis.
Although it is necessary to better understand the function of
the risk alleles identiﬁed by this study, the results may identify
genetic proﬁles that can be used to determine appropriate thera-
peutic interventions. To this point, two susceptibility loci are of
particular therapeutic interest in sJIA: the class II HLA locus
and HDAC9, encoding histone deacetylase 9. Given that class II
HLA molecules present peptide antigens to T-cell receptors on
CD4+ T cells, resulting in their activation, one may predict that
Figure 3 Comparison of the genetic architecture of systemic juvenile idiopathic arthritis (sJIA) with seronegative polyarticular and oligoarticular
(polygo) JIA. Kernel density plots display the distribution of polygo-wGRS in sJIA cases and controls from the full study collection (A). p Value was
calculated with the Wilcoxon rank-sum test. Receiver operator characteristic (ROC) curves with area under the curve (AUC) calculations demonstrate
the performance of polygo-wGRS at predicting sJIA status in the full collection (B). Q–Q plots show the level of association of subsets of
polygoJIA-associated single nucleotide polymorphisms in the sJIA population (C).
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therapeutic modulation of T-cell activation would be an effect-
ive strategy in the treatment of sJIA. In fact, abatacept, which
reduces T-cell activation through costimulatory inhibition, has
shown promising results in children with the chronic, persistent
arthritis of sJIA23 24—a subset of patients with sJIA who are par-
ticularly refractory to therapeutic intervention.5 Based on these
observations, it may be reasonable to use abatacept in children
with sJIA. HDAC9 confers important epigenetic effects through
deacetylation of histone proteins, while also regulating critical
innate immune processes, including Toll-like receptor signalling
and the development of regulatory T cells, via deacetylation of
non-histone targets.25–28 Despite the fact that HDAC9 was only
suggestively associated with sJIA, a pilot study of the non-
speciﬁc HDAC inhibitor, gavinostat, produced promising pre-
liminary results in children with sJIA,29 raising the possibility
that HDAC inhibition represents another plausible targeted
therapeutic strategy in sJIA.
At a time when an emphasis is being placed on the personal-
isation of medicine, it is important that we move away from
broad classiﬁcations based on non-speciﬁc clinical observations
and move towards the use of molecular and genetic data in
establishing diagnoses, as well as pathophysiology. In turn, clin-
ical practice will advance as these data are translated into tar-
geted therapeutic approaches. Perhaps it is time to separate
this condition from JIA all together to make clear that it is
fundamentally different from any other form of JIA and needs
to be considered and treated differently. Given that the
currently available treatments for this condition are still
imperfect, it remains imperative to continue to employ con-
temporary investigative approaches in sJIA, to elucidate its
pathophysiology and to identify the next generation of thera-
peutic strategies.
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